{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:18:05Z","timestamp":1768270685844,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G-1903"],"award-info":[{"award-number":["G-1903"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G-1903"],"award-info":[{"award-number":["G-1903"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G-1903"],"award-info":[{"award-number":["G-1903"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson's UK","doi-asserted-by":"publisher","award":["G-1903"],"award-info":[{"award-number":["G-1903"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000377","name":"Dunhill Medical Trust","doi-asserted-by":"publisher","award":["RPGF1906\\154"],"award-info":[{"award-number":["RPGF1906\\154"]}],"id":[{"id":"10.13039\/501100000377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000377","name":"Dunhill Medical Trust","doi-asserted-by":"publisher","award":["RPGF1906\\154"],"award-info":[{"award-number":["RPGF1906\\154"]}],"id":[{"id":"10.13039\/501100000377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000377","name":"Dunhill Medical Trust","doi-asserted-by":"publisher","award":["RPGF1906\\154"],"award-info":[{"award-number":["RPGF1906\\154"]}],"id":[{"id":"10.13039\/501100000377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000377","name":"Dunhill Medical Trust","doi-asserted-by":"publisher","award":["RPGF1906\\154"],"award-info":[{"award-number":["RPGF1906\\154"]}],"id":[{"id":"10.13039\/501100000377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) is the fastest growing neurological condition worldwide. Recent theories suggest that symptoms of PD may arise due to spread of Lewy-body pathology where the process begins in the gut and propagate transynaptically via the vagus nerve to the central nervous system. In PD, gait impairments are common motor manifestations that are progressive and can appear early in the disease course. As therapies to mitigate gait impairments are limited, novel interventions targeting these and their consequences, i.e., reducing the risk of falls, are urgently needed. Non-invasive vagus nerve stimulation (nVNS) is a neuromodulation technique targeting\u00a0the vagus nerve. We recently showed in a small pilot trial that a single dose of nVNS improved (decreased) discrete gait variability characteristics in those receiving active stimulation relative to those receiving sham stimulation. Further multi-dose, multi-session studies are needed to assess the safety and tolerability of the stimulation and if improvement in gait is sustained over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>This will be an investigator-initiated, single-site, proof-of-concept, double-blind sham-controlled randomised pilot trial in 40 people with PD. Participants will be randomly assigned on a 1:1 ratio to receive either active or sham transcutaneous cervical VNS. All participants will undergo comprehensive cognitive, autonomic and gait assessments during three sessions over 24\u00a0weeks, in addition to remote monitoring of ambulatory activity and falls, and exploratory analyses of cholinergic peripheral plasma markers. The primary outcome measure is the safety and tolerability of multi-dose nVNS in PD. Secondary outcomes include improvements in gait, cognition and autonomic function that will be summarised using descriptive statistics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study will report on the proportion of eligible and enrolled patients, rates of eligibility and reasons for ineligibility. Adverse events will be recorded informing on the safety and device tolerability in PD. This study will additionally provide us with information for sample size calculations for future studies and evidence whether improvement in gait control is enhanced when nVNS is delivered repeatedly and sustained over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial is prospectively registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.isrctn.com\/ISRCTN19394828\">www.isrctn.com\/ISRCTN19394828<\/jats:ext-link>. Registered August 23, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03081-1","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T05:14:42Z","timestamp":1675401282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson\u2019s: a study protocol"],"prefix":"10.1186","volume":"23","author":[{"given":"Hilmar P.","family":"Sigurdsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Alcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Pienaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Want","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John-Paul","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison J.","family":"Yarnall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"3081_CR1","doi-asserted-by":"publisher","unstructured":"Deane KHO, Flaherty H, Daley DJ, Pascoe R, Penhale B, Clarke CE, et al. Priority setting partnership to identify the top 10 research priorities for the management of parkinson\u2019s disease. BMJ Open.\u00a02015;4. https:\/\/doi.org\/10.1136\/bmjopen-2014-006434.","DOI":"10.1136\/bmjopen-2014-006434"},{"key":"3081_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.26110","volume":"30","author":"B Galna","year":"2015","unstructured":"Galna B, Lord S, Burn DJ, Rochester L. Progression of gait dysfunction in incident parkinson\u2019s disease: impact of medication and phenotype. Mov Disord. 2015;30:359\u201367. https:\/\/doi.org\/10.1002\/mds.26110.","journal-title":"Mov Disord"},{"key":"3081_CR3","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/mds.26742","volume":"31","author":"S Lord","year":"2016","unstructured":"Lord S, Galna B, Yarnall AJ, Coleman S, Burn DJ, Rochester L. Predicting first fall in newly diagnosed parkinson\u2019s disease: insights from a fall-naive cohort. Mov Disord. 2016;31:1829\u201336. https:\/\/doi.org\/10.1002\/mds.26742.","journal-title":"Mov Disord"},{"key":"3081_CR4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/WNL.0000000000003840","volume":"88","author":"L Rochester","year":"2017","unstructured":"Rochester L, Galna B, Lord S, Yarnall AJ, Morris R, Duncan GW, et al. Decrease in A\u03b242 predicts dopa-resistant gait progression in early parkinson disease. Neurology. 2017;88:1501\u201311. https:\/\/doi.org\/10.1212\/WNL.0000000000003840.","journal-title":"Neurology"},{"key":"3081_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2014.00249","volume":"6","author":"S Lord","year":"2014","unstructured":"Lord S, Galna B, Coleman S, Yarnall AJ, Burn DJ, Rochester L. Cognition and gait show a selective pattern of association dominated by phenotype in incident parkinson\u2019s disease. Front Aging Neurosci. 2014;6:1\u20139. https:\/\/doi.org\/10.3389\/fnagi.2014.00249.","journal-title":"Front Aging Neurosci"},{"key":"3081_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/gerona\/glx071","volume":"72","author":"R Morris","year":"2017","unstructured":"Morris R, Lord S, Lawson RA, Coleman S, Galna B, Duncan GW, et al. Gait rather than cognition predicts decline in specific cognitive domains in early parkinson\u2019s disease. Journals Gerontol - Ser A Biol Sci Med Sci. 2017;72:1656\u201362. https:\/\/doi.org\/10.1093\/gerona\/glx071.","journal-title":"Journals Gerontol - Ser A Biol Sci Med Sci"},{"key":"3081_CR7","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1093\/brain\/aws207","volume":"135","author":"L Rochester","year":"2012","unstructured":"Rochester L, Yarnall AJ, Baker MR, David RV, Lord SS, Galna B, et al. Cholinergic dysfunction contributes to gait disturbance in early parkinson\u2019s disease. Brain. 2012;135:2779\u201388. https:\/\/doi.org\/10.1093\/brain\/aws207.","journal-title":"Brain"},{"key":"3081_CR8","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/mds.23932","volume":"26","author":"AJ Yarnall","year":"2011","unstructured":"Yarnall AJ, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in parkinson\u2019s disease. Mov Disord. 2011;26:2496\u2013503. https:\/\/doi.org\/10.1002\/mds.23932.","journal-title":"Mov Disord"},{"key":"3081_CR9","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/mds.25360","volume":"28","author":"AJ Yarnall","year":"2013","unstructured":"Yarnall AJ, Rochester L, Baker MR, David R, Khoo TK, Duncan GW, et al. Short latency afferent inhibition: a biomarker for mild cognitive impairment in parkinson\u2019s disease? Mov Disord. 2013;28:1285\u20138. https:\/\/doi.org\/10.1002\/mds.25360.","journal-title":"Mov Disord"},{"key":"3081_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mds.28453","volume":"36","author":"J Wilson","year":"2020","unstructured":"Wilson J, Yarnall AJ, Craig CE, Galna B, Lord S, Morris R, et al. Cholinergic basal forebrain volumes predict gait decline in parkinson\u2019s disease. Mov Disord. 2020;36:611\u201321. https:\/\/doi.org\/10.1002\/mds.28453.","journal-title":"Mov Disord"},{"key":"3081_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/mds.28977","volume":"37","author":"HP Sigurdsson","year":"2022","unstructured":"Sigurdsson HP, Yarnall AJ, Galna B, Lord S, Alcock L, Lawson RA, et al. Gait-related metabolic covariance networks at rest in parkinson\u2019s disease. Mov Disord. 2022;37:1222\u201334. https:\/\/doi.org\/10.1002\/mds.28977.","journal-title":"Mov Disord"},{"key":"3081_CR12","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1172\/JCI42642","volume":"120","author":"C Karachi","year":"2010","unstructured":"Karachi C, Grabli D, Bernard FA, Tand\u00e9 D, Wattiez N, Belaid H, et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in parkinson disease. J Clin Invest. 2010;120:2745\u201354. https:\/\/doi.org\/10.1172\/JCI42642.","journal-title":"J Clin Invest"},{"key":"3081_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JCT, et al. Rivastigmine for gait stability in patients with parkinson\u2019s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:249\u201358. https:\/\/doi.org\/10.1016\/S1474-4422(15)00389-0.","journal-title":"Lancet Neurol"},{"key":"3081_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamaneurol.2017.3762","volume":"75","author":"J Gratwicke","year":"2018","unstructured":"Gratwicke J, Zrinzo L, Kahan J, Peters A, Beigi M, Akram H, et al. Bilateral deep brain stimulation of the nucleus basalis of meynert for parkinson disease dementia a randomized clinical trial. JAMA Neurol. 2018;75:169\u201378. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3762.","journal-title":"JAMA Neurol"},{"key":"3081_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.brs.2015.12.007","volume":"9","author":"DR Hulsey","year":"2016","unstructured":"Hulsey DR, Hays SA, Khodaparast N, Ruiz A, Das P, Rennaker RL, et al. Reorganization of motor cortex by vagus nerve stimulation requires cholinergic innervation. Brain Stimul. 2016;9:174\u201381. https:\/\/doi.org\/10.1016\/j.brs.2015.12.007.","journal-title":"Brain Stimul"},{"key":"3081_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neurobiolaging.2016.03.030","volume":"43","author":"SA Hays","year":"2016","unstructured":"Hays SA, Ruiz A, Bethea T, Khodaparast N, Carmel JB, Rennaker RL, et al. Vagus nerve stimulation during rehabilitative training enhances recovery of forelimb function after ischemic stroke in aged rats. Neurobiol Aging. 2016;43:111\u20138. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.03.030.","journal-title":"Neurobiol Aging"},{"key":"3081_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neubiorev.2021.04.018","volume":"127","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhan G, Cai Z, Jiao B, Zhao Y, Li S, et al. Vagus nerve stimulation in brain diseases: therapeutic applications and biological mechanisms. Neurosci Biobehav Rev. 2021;127:37\u201353. https:\/\/doi.org\/10.1016\/j.neubiorev.2021.04.018.","journal-title":"Neurosci Biobehav Rev"},{"key":"3081_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/JIR.S163248","volume":"11","author":"RL Johnson","year":"2018","unstructured":"Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018;11:203\u201313. https:\/\/doi.org\/10.2147\/JIR.S163248.","journal-title":"J Inflamm Res"},{"key":"3081_CR19","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.brs.2014.11.018","volume":"8","author":"E Frangos","year":"2015","unstructured":"Frangos E, Ellrich J, Komisaruk BR. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: FMRI evidence in humans. Brain Stimul. 2015;8:624\u201336. https:\/\/doi.org\/10.1016\/j.brs.2014.11.018.","journal-title":"Brain Stimul"},{"key":"3081_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroscience.2011.05.024","volume":"189","author":"JA Nichols","year":"2011","unstructured":"Nichols JA, Nichols AR, Smirnakis SM, Engineer ND, Kilgard MP, Atzori M. Vagus nerve stimulation modulates cortical synchrony and excitability through the activation of muscarinic receptors. Neuroscience. 2011;189:207\u201314. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.05.024.","journal-title":"Neuroscience"},{"key":"3081_CR21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.brs.2017.08.008","volume":"10","author":"AQ Farrand","year":"2017","unstructured":"Farrand AQ, Helke KL, Gregory RA, Gooz MB, Hinson VK, Boger HA. Vagus nerve stimulation improves locomotion and neuronal populations in a model of parkinson\u2019s disease. Brain Stimul. 2017;10:1045\u201354. https:\/\/doi.org\/10.1016\/j.brs.2017.08.008.","journal-title":"Brain Stimul"},{"key":"3081_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(21)00475-X","volume":"397","author":"J Dawson","year":"2021","unstructured":"Dawson J, Liu CY, Francisco GE, Cramer SC, Wolf SL, Dixit A, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet. 2021;397:1545\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(21)00475-X.","journal-title":"Lancet"},{"key":"3081_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/17434440.2021.1969913","author":"HP Sigurdsson","year":"2021","unstructured":"Sigurdsson HP, Raw R, Hunter H, Baker MR, Taylor J-P, Rochester L, et al. Non-invasive vagus nerve stimulation in parkinson\u2019s disease: current status and future prospects. Expert Rev Med Devices. 2021. https:\/\/doi.org\/10.1080\/17434440.2021.1969913.","journal-title":"Expert Rev Med Devices"},{"key":"3081_CR24","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/mds.27664","volume":"34","author":"R Morris","year":"2019","unstructured":"Morris R, Yarnall AJ, Hunter H, Taylor JP, Baker MR, Rochester L. Noninvasive vagus nerve stimulation to target gait impairment in parkinson\u2019s disease. Mov Disord. 2019;34:918\u20139. https:\/\/doi.org\/10.1002\/mds.27664.","journal-title":"Mov Disord"},{"key":"3081_CR25","doi-asserted-by":"publisher","unstructured":"Hausdorff JM. Gait variability\u202f: methods , modeling and meaning example of increased stride time variability in elderly fallers quantification of stride-to-stride fluctuations 2005;9:1\u20139. https:\/\/doi.org\/10.1186\/1743-Received.","DOI":"10.1186\/1743-Received"},{"key":"3081_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/bmj.e7586","volume":"2013","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, SPIRIT, et al. Explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;2013:346. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ"},{"key":"3081_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"2013","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, SPIRIT, et al. statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;2013:158. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"key":"3081_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181\u20134. https:\/\/doi.org\/10.1136\/jnnp.55.3.181.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3081_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427\u201342. https:\/\/doi.org\/10.1212\/wnl.17.5.427.","journal-title":"Neurology"},{"key":"3081_CR30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with parkinson\u2019s disease. Mov Disord. 2007;22:1689\u2013707. https:\/\/doi.org\/10.1002\/mds.21507.","journal-title":"Mov Disord"},{"key":"3081_CR31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/gerona\/gls255","volume":"68","author":"S Lord","year":"2013","unstructured":"Lord S, Galna B, Verghese J, Coleman S, Burn DJ, Rochester L. Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci. 2013;68:820\u20137. https:\/\/doi.org\/10.1093\/gerona\/gls255.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3081_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2307\/2529712","volume":"31","author":"SJ Pocock","year":"1975","unstructured":"Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103\u201315. https:\/\/doi.org\/10.2307\/2529712.","journal-title":"Biometrics"},{"key":"3081_CR33","doi-asserted-by":"publisher","DOI":"10.3758\/s13423-021-01970-5","author":"F Sella","year":"2021","unstructured":"Sella F, Raz G, Cohen KR. When randomisation is not good enough: matching groups in intervention studies. Psychon Bull Rev. 2021. https:\/\/doi.org\/10.3758\/s13423-021-01970-5.","journal-title":"Psychon Bull Rev"},{"key":"3081_CR34","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.brs.2018.08.010","volume":"11","author":"J Redgrave","year":"2018","unstructured":"Redgrave J, Day D, Leung H, Laud PJ, Ali A, Lindert R, et al. Safety and tolerability of transcutaneous vagus nerve stimulation in humans; a systematic review. Brain Stimul. 2018;11:1225\u201338. https:\/\/doi.org\/10.1016\/j.brs.2018.08.010.","journal-title":"Brain Stimul"},{"key":"3081_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1113\/jphysiol.1934.sp003176","volume":"82","author":"GL Brown","year":"1934","unstructured":"Brown GL, Eccles JC. The action of a single vagal volley on the rhythm of the heart beat. J Physiol. 1934;82:211\u201341. https:\/\/doi.org\/10.1113\/jphysiol.1934.sp003176.","journal-title":"J Physiol"},{"key":"3081_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40814-017-0158-3","volume":"4","author":"KL Best","year":"2018","unstructured":"Best KL, Miller WC, Routhier F, Eng JJ. Feasibility of the trial procedures for a randomized controlled trial of a community-based peer-led wheelchair training program for older adults. Pilot Feasibility Stud. 2018;4:1\u201312. https:\/\/doi.org\/10.1186\/s40814-017-0158-3.","journal-title":"Pilot Feasibility Stud"},{"key":"3081_CR37","doi-asserted-by":"crossref","unstructured":"North American Society of Pacing and Electrophysiology TF of the ES of C. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Eur Heart J. 1996;17:354\u201381.","DOI":"10.1093\/oxfordjournals.eurheartj.a014868"},{"key":"3081_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The parkinson\u2019s disease questionnaire (pdq-39): development and validation of a parkinson\u2019s disease summary index score. Age Ageing. 1997;26:353\u20137. https:\/\/doi.org\/10.1093\/ageing\/26.5.353.","journal-title":"Age Ageing"},{"key":"3081_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","volume":"17","author":"JA Yesavage","year":"1982","unstructured":"Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37\u201349. https:\/\/doi.org\/10.1016\/0022-3956(82)90033-4.","journal-title":"J Psychiatr Res"},{"key":"3081_CR40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, moca: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"key":"3081_CR41","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement disorder society-sponsored revision of the unified parkinson\u2019s disease rating scale (mds-updrs): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"3081_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ageing\/afr051","volume":"40","author":"HC Roberts","year":"2011","unstructured":"Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40:423\u20139. https:\/\/doi.org\/10.1093\/ageing\/afr051.","journal-title":"Age Ageing"},{"key":"3081_CR43","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489\u201395. https:\/\/doi.org\/10.1503\/cmaj.050051.","journal-title":"CMAJ"},{"key":"3081_CR44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1023\/B:QURE.0000021689.86296.e4","volume":"13","author":"DA Revicki","year":"2004","unstructured":"Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, et al. Gastroparesis cardinal symptom index ( GCSI ): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004;13:833\u201344.","journal-title":"Qual Life Res"},{"key":"3081_CR45","doi-asserted-by":"publisher","unstructured":"Jette AM, Haley SM, Coster WJ, Kooyoomjian JT, Levenson S, Heeren T, et al. Late life function and disability instrument: II.development and evaluation of the function component. Journals Gerontol - Ser A Biol Sci Med Sci.\u00a02002;57:M217\u201322. https:\/\/doi.org\/10.1093\/gerona\/57.4.M217.","DOI":"10.1093\/gerona\/57.4.M217"},{"key":"3081_CR46","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/mds.22989","volume":"25","author":"JH Friedman","year":"2010","unstructured":"Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, et al. Fatigue rating scales critique and recommendations by the movement disorders society task force on rating scales for parkinson\u2019s disease. Mov Disord. 2010;25:805\u201322. https:\/\/doi.org\/10.1002\/mds.22989.","journal-title":"Mov Disord"},{"key":"3081_CR47","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jpainsymman.2006.05.021","volume":"32","author":"P Hagell","year":"2006","unstructured":"Hagell P, H\u00f6glund A, Reimer J, Eriksson B, Knutsson I, Widner H, et al. Measuring fatigue in parkinson\u2019s disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manage. 2006;32:420\u201332. https:\/\/doi.org\/10.1016\/j.jpainsymman.2006.05.021.","journal-title":"J Pain Symptom Manage"},{"key":"3081_CR48","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s11136-011-0009-2","volume":"21","author":"RG Elbers","year":"2012","unstructured":"Elbers RG, Rietberg MB, Van Wegen EEH, Verhoef J, Kramer SF, Terwee CB, et al. Self-report fatigue questionnaires in multiple sclerosis, parkinson\u2019s disease and stroke: a systematic review of measurement properties. Qual Life Res. 2012;21:925\u201344. https:\/\/doi.org\/10.1007\/s11136-011-0009-2.","journal-title":"Qual Life Res"},{"key":"3081_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parkreldis.2016.07.006","volume":"31","author":"K Smulders","year":"2016","unstructured":"Smulders K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. Pharmacological treatment in parkinson\u2019s disease: Effects on gait. Park Relat Disord. 2016;31:3\u201313. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.07.006.","journal-title":"Park Relat Disord"},{"key":"3081_CR50","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1002\/mds.25545","volume":"28","author":"S Lord","year":"2013","unstructured":"Lord S, Galna B, Rochester L. Moving forward on gait measurement: toward a more refined approach. Mov Disord. 2013;28:1534\u201343. https:\/\/doi.org\/10.1002\/mds.25545.","journal-title":"Mov Disord"},{"key":"3081_CR51","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1109\/JBHI.2015.2419317","volume":"20","author":"S Del Din","year":"2016","unstructured":"Del Din S, Godfrey A, Rochester L. Validation of an accelerometer to quantify a comprehensive battery of gait characteristics in healthy older adults and parkinson\u2019s disease: toward clinical and at home use. IEEE J Biomed Heal Informatics. 2016;20:838\u201347. https:\/\/doi.org\/10.1109\/JBHI.2015.2419317.","journal-title":"IEEE J Biomed Heal Informatics"},{"key":"3081_CR52","doi-asserted-by":"publisher","first-page":"N1","DOI":"10.1088\/1361-6579\/38\/1\/N1","volume":"38","author":"A Hickey","year":"2017","unstructured":"Hickey A, Del Din S, Rochester L, Godfrey A. Detecting free-living steps and walking bouts: validating an algorithm for macro gait analysis. Physiol Meas. 2017;38:N1-15. https:\/\/doi.org\/10.1088\/1361-6579\/38\/1\/N1.","journal-title":"Physiol Meas"},{"key":"3081_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/tmj.2015.0026","volume":"22","author":"JM Fisher","year":"2016","unstructured":"Fisher JM, Hammerla NY, Rochester L, Andras P, Walker RW. Body-worn sensors in parkinson\u2019s disease: evaluating their acceptability to patients. Telemed e-Health. 2016;22:63\u20139. https:\/\/doi.org\/10.1089\/tmj.2015.0026.","journal-title":"Telemed e-Health"},{"key":"3081_CR54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.maturitas.2015.04.003","volume":"82","author":"A Godfrey","year":"2015","unstructured":"Godfrey A, Lara J, Del Din S, Hickey A, Munro CA, Wiuff C, et al. iCap: Instrumented assessment of physical capability. Maturitas. 2015;82:116\u201322. https:\/\/doi.org\/10.1016\/j.maturitas.2015.04.003.","journal-title":"Maturitas"},{"key":"3081_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/gps.930100306","volume":"10","author":"CG Nicholl","year":"1995","unstructured":"Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes KA, et al. The cognitive drug research computerized assessment system in the evaluation of early dementia-is speed of the essence? Int J Geriatr Psychiatry. 1995;10:199\u2013206. https:\/\/doi.org\/10.1002\/gps.930100306.","journal-title":"Int J Geriatr Psychiatry"},{"key":"3081_CR56","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.04.009","volume":"27","author":"RA Lawson","year":"2016","unstructured":"Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, et al. Cognitive decline and quality of life in incident parkinson\u2019s disease: the role of attention. Park Relat Disord. 2016;27:47\u201353. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.009.","journal-title":"Park Relat Disord"},{"key":"3081_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000106735","volume":"5","author":"TW Robbins","year":"1994","unstructured":"Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994;5:266\u201381. https:\/\/doi.org\/10.1159\/000106735.","journal-title":"Dementia"},{"key":"3081_CR58","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3233\/JPD-212581","volume":"11","author":"RA Lawson","year":"2021","unstructured":"Lawson RA, Williams-Gray CH, Camacho M, Duncan GW, Khoo TK, Breen DP, et al. Which neuropsychological tests? predicting cognitive decline and dementia in parkinson\u2019s disease in the icicle-pd cohort. J Parkinsons Dis. 2021;11:1297\u2013308. https:\/\/doi.org\/10.3233\/JPD-212581.","journal-title":"J Parkinsons Dis"},{"key":"3081_CR59","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/j.1532-5415.2005.53455.x","volume":"53","author":"SE Lamb","year":"2005","unstructured":"Lamb SE, J\u00f8rstad-Stein EC, Hauer K, Becker C. Development of a common outcome data set for fall injury prevention trials: the prevention of falls network europe consensus. J Am Geriatr Soc. 2005;53:1618\u201322. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53455.x.","journal-title":"J Am Geriatr Soc"},{"key":"3081_CR60","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1080\/09638288.2017.1329357","volume":"40","author":"H Hunter","year":"2018","unstructured":"Hunter H, Rochester L, Morris R, Lord S. Longitudinal falls data in parkinson\u2019s disease: feasibility of fall diaries and effect of attrition. Disabil Rehabil. 2018;40:2236\u201341. https:\/\/doi.org\/10.1080\/09638288.2017.1329357.","journal-title":"Disabil Rehabil"},{"issue":"11","key":"3081_CR61","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1007\/s00415-017-8620-y","volume":"264","author":"S Lord","year":"2017","unstructured":"Lord S, Galna B, Yarnall AJ, Morris R, Coleman S, Burn D, et al. Natural history of falls in an incident cohort of parkinson\u2019s disease: early evolution, risk and protective features. J Neurol. 2017;264(11):2268\u201376. https:\/\/doi.org\/10.1007\/s00415-017-8620-y.","journal-title":"J Neurol"},{"key":"3081_CR62","unstructured":"FDA. Bioanalytical method validation: guidance for industry. 2018:1\u201337. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf."},{"key":"3081_CR63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"3081_CR64","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ner.12879","volume":"22","author":"J Tarn","year":"2019","unstructured":"Tarn J, Legg S, Mitchell S, Simon B, Ng WF. The effects of noninvasive vagus nerve stimulation on fatigue and immune responses in patients with primary sj\u00f6gren\u2019s syndrome. Neuromodulation. 2019;22:580\u20135. https:\/\/doi.org\/10.1111\/ner.12879.","journal-title":"Neuromodulation"},{"key":"3081_CR65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/mds.27662","volume":"34","author":"B Mondal","year":"2019","unstructured":"Mondal B, Choudhury S, Simon B, Baker MR, Kumar H. Noninvasive vagus nerve stimulation improves gait and reduces freezing of gait in parkinson\u2019s disease. Mov Disord. 2019;34:917\u20138. https:\/\/doi.org\/10.1002\/mds.27662.","journal-title":"Mov Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03081-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03081-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T05:15:45Z","timestamp":1675401345000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03081-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3081"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03081-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"assertion":[{"value":"18 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was received in 2021 (the East Midlands\u2014Derby Research Ethics Committee, REC reference: 21\/EM\/0177) and recruitment started in January 2022. The study has been prospectively registered with the ISRCTN registry (ISRCTN19394828, registered on August 23, 2021). This study is conducted in accordance with the Declaration of Helsinki. All participants are required to provide written informed consent by signing all study form(s), which are witnessed by an appropriately qualified and delegated member of the research team, prior to the completion of all study-specific procedures\/investigations. Any protocol amendments will be approved by the appropriate research ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HPS. has received support from Guarantors of Brain and the Newcastle Wellcome Trust Translational Partnership for attending conferences. His salary is paid by grants from Parkinson\u2019s UK and Dunhill Medical Trust awarded to the PI AJY. HH: Salary is supported by the NIHR Newcastle clinical Research Facility (CRF) infrastructure. LA\u2019s salary is supported by the NIHR Newcastle Clinical Research Facility (CRF) infrastructure, and LA has received grants from the Economic and Social Research Council (ESRC), Medical Research Council (MRC), Parkinson\u2019s UK, and the Royal College of Radiologists. RW: None. IP: None. EW: None. MRB is employed by the NHS (Newcastle upon Tyne NHS Foundation Trust) and Newcastle University. His research is currently funded by the NIHR, MRC, EPSRC, LifeArc, MNDA and MyName\u20195 Dodie Foundation. JPT is supported by Newcastle NIHR BRC. He has received speaker fees from GE Healthcare and Bial, has received funding from Sosei-Heptares, and has consulted for Kyowa-Kirin. LR\u2019s research program is supported in part by grants from the MRC, European Union, Parkinson\u2019s UK, NIHR BRC, Cure Parkinson\u2019s Trust, Health Research Council New Zealand, Dunhill Medical, and Stroke Association. AJY is supported by the Newcastle NIHR BRC plus grants from Parkinson\u2019s UK, The Michael J. Fox Foundation, EU IMI, NIHR, Cure Parkinson\u2019s Trust, Lewy Body Society, Intercept Pharmaceuticals, and the Weston Brain Institute. She has received honoraria from Teva-Lundbeck, GE Healthcare, Bial and Parkinson\u2019s Academy and sponsorship from Teva-Lundbeck, UCB, GlaxoSmithKline, Genus, Britannia, and AbbVie for attending conferences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}